This article is more than 5 years old. Information may no longer be current.

FINESSE-ANGIO

Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events-Angiographic

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Trial was a substudy of the FINESSE trial and was designed to evaluate the acute effects of half-dose reteplase plus abciximab, abciximab alone or abciximab administered directly before primary PCI on infarct-related artery patency and angiographic correlates of coronary microcirculatory function.

Design: randomized
Patients: 637
Centers: multicenter
Countries: international

Results: Reteplase plus abciximab led to higher rates of baseline infarct-related artery patency when compared with abciximab alone (76.1% vs. 43.7%; P<.0001) and when abciximab was administered immediately before PCI procedure (76.1% vs. 32.7%; P<.0001). Researchers did not report any significant differences in the post-PCI thrombolysis in MI or the rates of post-PCI TIMI flow grade 3, myocardial blush grade 2/3.

Published in: J Am Coll Cardiol Intv. 2010;3:1284-1291.

Read more about the FINESSE-ANGIO trial here.